ACOG and SMFM* recently issued Committee Opinion on Cell-free DNA Screening For Fetal Aneuploidy, Number 640, September 2015 (ahead of print on 26th June 2015)

In this issue, the committee stated that “noninvasive prenatal screening that uses cell-free DNA from the plasma of pregnant women offers tremendous potential as a screening method for fetal aneuploidy”. However, “patients should be counseled that cell-free DNA screening does not replace the precision obtained with diagnostic tests, such as chorionic villus sampling or amniocentesis” and, furthermore, “management decisions, including termination of pregnancy, should not be based on the results of the cell-free DNA screening alone”.

Download Complete Article

* ACOG – The American College of Obstetricians and Gynecologists and SMFM – Society for Maternal-Fetal Medicine